Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Breast Neoplasms 17Neoplasms 14Neoplasm Metastasis 10Ovarian Neoplasms 9Melanoma 7Leukemia, Lymphocytic, Chronic, B-Cell 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Urinary Bladder Neoplasms 6Small Cell Lung Carcinoma 6Recurrence 6Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Thyroid Neoplasms 5Thyroid Cancer, Papillary 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Lung Neoplasms 5Hematologic Neoplasms 5Head and Neck Neoplasms 5Endometrial Neoplasms 5Colonic Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Lymphoma 4Leukemia, Myeloid, Acute 4Urothelial Cancer 3Stomach Neoplasms 3Sarcoma 3Salivary Gland Neoplasms 3

Interventions

mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Has announcements × Neurofibroma × Clear all
NCT03962543 2026-05-06

ReNeu

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2 Active not recruiting
114 enrolled 25 charts 1 FDA
CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡